JY
CMPX icon

Jeff Yass’s Compass Therapeutics CMPX Stock Holding History

Jeff Yass’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123K Sell
56,200
-7,200
-11% -$21.3K ﹤0.01% 12352
2026
Q1 		$335K Buy
+63,400
New +$366K ﹤0.01% 10624
2025
Q2 		– Sell
-130,800
Closed -$249K – 12762
2025
Q1 		$249K Buy
+130,800
New +$348K ﹤0.01% 10488

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jeff Yass's CMPX Position: Q2 2026 in Review

Jeff Yass increased its Compass Therapeutics (CMPX) stake by 96% in Q2 2026, buying an estimated $447K and bringing the position to 308,295 shares worth $675K. The position accounts for ﹤0.01% of the portfolio, ranked #9198.

Jeff Yass first reported a position in CMPX in Q3 2022 and has held it in 14 quarters since. The position peaked at $2.56M in Q1 2023. 213 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Jeff Yass held 308,295 shares of Compass Therapeutics worth $675K as of Q2 2026.
  • Jeff Yass bought 151,270 Compass Therapeutics shares in Q2 2026, an estimated $447K.
  • Compass Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #9198 holding.
  • Jeff Yass first reported a position in Compass Therapeutics in Q3 2022 and has held it in 14 quarters since.
  • Jeff Yass's Compass Therapeutics position peaked at $2.56M in Q1 2023.
  • 213 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.